Biocompatibility Testing of Medical Fibers: Standards, Methods, and Applications

Medical fibers form the structural backbone of sutures, wound dressings, hernia meshes, vascular grafts, and implantable textile devices, making biocompatibility testing a decisive factor for patient safety and regulatory approval. Biocompatibility evaluation of medical fibers, performed in accordance with the ISO 10993 series, GB/T 16886, and ASTM standards, assesses cytotoxicity, sensitization, irritation, systemic toxicity, hemocompatibility, and local implantation effects. This article explains the standards framework, sample requirements, core test items, laboratory methods, and typical applications of biocompatibility testing for medical fiber materials.

Technical Overview

Biocompatibility is the ability of a biomaterial to perform its intended function in a specific clinical application without producing an unacceptable local or systemic host response. Medical fibers cover a broad range of materials, including natural polymers such as collagen, silk fibroin, chitosan, alginate, and cellulose, as well as synthetic polymers such as polyglycolide (PGA), polylactide (PLA), poly(lactide-co-glycolide) (PLGA), polydioxanone (PDO), polypropylene, polyester (PET), polyamide, polyurethane, and polytetrafluoroethylene (PTFE). Because fiber manufacturing involves spinning, drawing, texturizing, braiding, weaving, knitting, coating, and sterilization, each process step can introduce extractable chemicals, residual monomers, processing aids, or degradation products that may affect biological safety.

The evaluation framework is governed by ISO 10993-1, Biological evaluation of medical devices - Evaluation and testing within a risk management process, which is adopted in China as the GB/T 16886 series and supplemented by ASTM F748 for the selection of generic biological test methods for materials. Test selection follows a risk-based matrix determined by:

• Nature of body contact: surface-contacting devices (intact skin, mucosal membranes, breached surfaces), externally communicating devices (indwelling catheters, blood-contacting circuits), or implant devices
• Duration of contact: limited contact (24 hours or less), prolonged contact (24 hours to 30 days), or permanent contact (more than 30 days)
• Physical form of the fiber: monofilament, multifilament, braid, woven or knitted fabric, nonwoven web, or hollow-fiber membrane
• Degradation behavior: non-absorbable fibers versus absorbable fibers that release degradation products over time

Testing is typically carried out by accredited third-party laboratories or in-house facilities operating under ISO/IEC 17025 quality systems, and the results are compiled into a biological evaluation plan and biological evaluation report reviewed by qualified toxicologists.

Testing Samples

Raw Fiber Materials

Monofilaments, multifilament yarns, staple fibers, and nonwoven webs may be submitted before device conversion to screen material safety at an early stage. Samples should be representative of production-scale lots and include any spinning finishes, sizing agents, coatings, or surface treatments applied during manufacturing.

Finished Fiber-Based Medical Devices

Sutures (absorbable and non-absorbable), hernia meshes, wound dressings, tissue-engineering scaffolds, vascular grafts, catheter components, and hemodialysis hollow-fiber membranes should be tested in their final finished form, including the sterilization method actually used in production (ethylene oxide, gamma irradiation, electron beam, or steam), since sterilization can generate residues or alter surface chemistry.

Extracts, Leachables, and Degradation Products

For most in vitro and in vivo assays, test articles are converted into aqueous and non-aqueous extracts according to ISO 10993-12. For absorbable fibers, hydrolytic and enzymatic degradation products are additionally generated and characterized according to ISO 10993-13 (polymers) and ISO 10993-15 (metals and alloys, where applicable).

Sample Submission Requirements

Submission typically includes documented material composition, supplier information, processing and sterilization history, intended use and contact classification, and sufficient sample quantity to complete all planned assays, including repeat testing if required.

Testing Items

Depending on the ISO 10993-1 classification, the following test items are commonly required for medical fiber products:

• In vitro cytotoxicity (ISO 10993-5)
• Sensitization and delayed-type hypersensitivity (ISO 10993-10)
• Skin, mucosal, and intracutaneous irritation or reactivity (ISO 10993-10, ISO 10993-23)
• Acute, subacute, and subchronic systemic toxicity (ISO 10993-11)
• Hemocompatibility: hemolysis, thrombogenicity, coagulation, platelet interaction, and complement activation (ISO 10993-4)
• Genotoxicity: bacterial reverse mutation, chromosomal aberration, and micronucleus assays (ISO 10993-3)
• Local effects after implantation in muscle, subcutaneous tissue, or bone (ISO 10993-6)
• Material-mediated pyrogenicity and bacterial endotoxin testing
• Chemical characterization of extractables and leachables with toxicological risk assessment (ISO 10993-18, ISO 10993-17)
• In vitro and in vivo degradation studies for absorbable fibers (ISO 10993-13, ISO 10993-15)
• Ethylene oxide and other sterilant residue analysis (ISO 10993-7)
• Carcinogenicity and reproductive or developmental toxicity, applied case by case for long-term and permanent implants

Testing Methods

Sample Preparation and Extraction

ISO 10993-12 defines extraction media, ratios, and conditions. Polar media such as physiological saline and cell culture medium, and non-polar media such as sesame seed oil, are used to extract both hydrophilic and lipophilic contaminants. Standardized ratios, such as 3 cm2 of surface area per milliliter or 0.2 g of material per milliliter, are applied, with extraction conditions (for example, 37 degrees Celsius for 72 hours, 50 degrees Celsius for 72 hours, 70 degrees Celsius for 24 hours, or 121 degrees Celsius for 1 hour) selected to exaggerate clinical exposure without altering the material itself.

In Vitro Cytotoxicity

The extract (elution) method using L929 mouse fibroblast cells combined with the MTT viability assay is the most widely applied approach under ISO 10993-5. Direct contact and agar diffusion methods are alternatives for low-density materials. A mean cell viability of at least 70 percent relative to the negative control indicates the fiber extract is non-cytotoxic.

Sensitization and Irritation

Sensitization is evaluated using the guinea pig maximization test, the Buehler test, or the murine local lymph node assay (LLNA) under ISO 10993-10. Irritation is assessed through the intracutaneous reactivity test in rabbits, where a primary irritation index of 0.4 or below is generally acceptable, or through skin irritation testing per ISO 10993-23, which also recognizes reconstructed human epidermis in vitro models as replacements for animal testing.

Hemocompatibility

ISO 10993-4 categorizes blood-device interactions into thrombosis, coagulation, platelet function, hematology, and complement system effects. Hemolysis testing, often conducted in line with ASTM F756, requires a hemolysis ratio below 5 percent for acceptance. Blood-contacting fibers, such as those used in vascular grafts, oxygenator membranes, and hemodialysis hollow fibers, additionally require thrombogenicity and complement activation (C3a, SC5b-9) assessment.

Systemic Toxicity and Implantation

Acute systemic toxicity is assessed by single intravenous or intraperitoneal injection of polar and non-polar extracts in mice, followed by subacute (14 to 28 days) or subchronic (up to 90 days) studies for prolonged-contact devices under ISO 10993-11. Local implantation effects are examined under ISO 10993-6 by implanting fiber specimens intramuscularly or subcutaneously and scoring histopathological endpoints such as inflammation, fibrosis, necrosis, and tissue ingrowth at 1, 4, 12, 26, or 52 weeks, depending on the intended duration of use.

Chemical Characterization, Genotoxicity, and Degradation

Chemical characterization under ISO 10993-18 employs FTIR spectroscopy, GC-MS, LC-MS, and ICP-MS to identify and quantify extractables and leachables, with results feeding into a toxicological risk assessment per ISO 10993-17. Genotoxicity screening per ISO 10993-3 uses the bacterial reverse mutation assay (OECD 471), the in vitro mammalian chromosomal aberration or mouse lymphoma assay (OECD 473 and 476), and the in vitro micronucleus assay (OECD 487). For absorbable fibers, degradation studies track mass loss, molecular weight decline by gel permeation chromatography, monomer release, and in vivo absorption with local tissue reaction over clinically relevant timeframes.

Applications

Biocompatibility testing supports the design, registration, and quality control of fiber-based medical products across nearly every clinical specialty:

• Absorbable sutures and barbed sutures made from PGA, PLGA, and PDO, requiring degradation and implantation evaluation in addition to the core endpoints
• Non-absorbable sutures of polypropylene, polyester, polyamide, and silk, requiring cytotoxicity, sensitization, irritation, and implantation data
• Hernia repair meshes and soft-tissue reinforcement fabrics, including coated and composite mesh constructions
• Advanced wound dressings based on alginate, chitosan, collagen, and hydrofiber technologies contacting breached skin
• Vascular grafts, stent-graft fabrics, and hemodialysis hollow-fiber membranes requiring comprehensive hemocompatibility panels
• Tissue-engineering scaffolds and regenerative medicine matrices where fiber architecture guides cell behavior
• Surgical gowns, drapes, and protective medical textiles evaluated through the surface-contact test set of cytotoxicity, irritation, and sensitization
• Urological, gastrointestinal, ophthalmic, and dental fiber-based devices with contact-specific test programs

Test reports from accredited third-party laboratories are accepted in support of NMPA registration in China, FDA 510(k) and PMA submissions in the United States, and CE marking under the EU Medical Device Regulation, streamlining access to global markets.

FAQ

Which standards govern biocompatibility testing of medical fibers?

The ISO 10993 series is the internationally recognized framework, and it is technically aligned with the Chinese GB/T 16886 series. ASTM standards such as ASTM F748 and ASTM F756 provide complementary guidance on test selection and hemolysis evaluation. The applicable standard set is determined by the classification of the finished device under ISO 10993-1.

How are tests selected for a specific medical fiber product?

Selection follows the ISO 10993-1 decision matrix based on body contact type and contact duration. For example, a wound dressing contacting breached skin for several days typically requires cytotoxicity, sensitization, and irritation testing, whereas an absorbable suture also requires systemic toxicity, implantation, genotoxicity screening, and degradation assessment.

What are the typical acceptance criteria?

Common acceptance thresholds include cell viability of at least 70 percent in the MTT assay, a hemolysis ratio below 5 percent, a primary irritation index of 0.4 or lower, no sensitization response exceeding negative controls, and implantation scores not significantly worse than the control material, all interpreted by a toxicologist within the overall risk assessment.

How long does biocompatibility testing take?

Cytotoxicity generally requires one to three weeks, irritation one to two weeks, sensitization four to eight weeks, and chemical characterization four to eight weeks depending on analytical complexity. Implantation studies may extend from 12 weeks to more than one year for permanent implants, so early planning of the biological evaluation plan is strongly recommended.

Is biocompatibility testing mandatory for regulatory submission?

Yes. Biocompatibility data are a core requirement for NMPA registration, FDA clearance or approval, and CE marking under the EU MDR. A documented biological evaluation file, combining chemical characterization, targeted testing, and literature-based toxicological assessment, is expected as part of the technical documentation.

Do medical fibers need retesting when manufacturing changes?

Material supplier changes, modified spinning or coating parameters, new sterilization methods, or changes in packaging that affect extractables should trigger a change impact evaluation. In many cases, updated chemical characterization per ISO 10993-18 can justify retaining existing biocompatibility conclusions without repeating the full test panel.